Lead Product(s) : Lefamulin Acetate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Nabriva Publishes Data Demonstrating the Potent Anti-Inflammatory Properties of XENLETA® (Lefamulin)
Details : XENLETA is the first intravenous and oral pleuromutilin approved for the systemic treatment of community acquired bacterial pneumonia (CABP) in adults, and also reduced pro-inflammatory cytokines comparable to that observed with dexamethasone.
Product Name : Xenleta
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 10, 2021
Lead Product(s) : Lefamulin Acetate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CB5064 Analog
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CohBar will test its CB5064 analogs in preclinical models of ARDS, to assess their potential as therapeutics for coronavirus disease 2019 (COVID-19) associated ARDS.
Product Name : CB5064 Analog
Product Type : Peptide
Upfront Cash : Inapplicable
May 05, 2020
Lead Product(s) : CB5064 Analog
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable